FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3129853752> ?p ?o ?g. }

• W3129853752 endingPage "06" @default.
• W3129853752 startingPage "PD12" @default.
• W3129853752 abstract "Abstract Background: Cytotoxic chemotherapy (CT) in combination with trastuzumab and pertuzumab (HP) is standard of care for patients (pts) diagnosed with HER2-positive early breast cancer (EBC). While highly effective, the toxicity associated with CT is challenging. In KRISTINE/TRIO-021, neoadjuvant T-DM1 was combined with pertuzumab (KP) and compared to standard TCHP. Pts. received six cycles of neoadjuvant treatment followed by adjuvant therapy (KP or HP). Pts. in the KP arm were allowed to receive standard adjuvant CT. Pathologic complete response (pCR) rate was significantly lower with KP versus TCHP and more pts. had disease progression prior to surgery with KP, resulting in a meaningfully lower event-free survival rate vs. the control (85.3% vs 94.2%). However, 3-year invasive disease-free survival was numerically similar in both arms. Neoadjuvant KP demonstrated less toxicity than standard CT, although treatment discontinuation was higher post-surgery. Association of KP and TCHP with treatment-related amenorrhea (TRA) in premenopausal EBC pts. has not been ascertained. Methods: All pts. with premenopausal status at study entry (those not meeting the menopause definition based on National Comprehensive Cancer Network Guidelines v3, 2012) and with menstrual period documented within 3 months of randomization, were independently evaluated for presence or absence of TRA by two reviewers. TRA, a prespecified exploratory endpoint of KRISTINE, was defined as cessation of menstruation for &gt;12 months in the absence of treatment with ovarian suppression or other interventions that can induce amenorrhea. Pts. were followed from the time of study entry through the 3-year follow up period after surgery. For cases with inconsistent determination between the two reviewers, a third reviewer adjudicated. TRA rates were calculated per arm, hormone-receptor (HR) status, adjuvant CT and age group. Proportions were compared by estimating the odds ratio (OR) and the 95% confidence interval. Results: Of 444 pts. enrolled, 205 were excluded based on being post-menopausal per NCCN guidelines. Of 239 pts. remaining, 56 were excluded due to insufficient data. The median age of pts. included was 40 years (range: 22-53) for TCHP and 42.5 (range: 23-52) for KP. TRA was observed in 55% (50/91) of pts. treated with TCHP compared to 30% (28/92) treated with KP (OR=2.79; 95% CI 1.52-5.12). In pts. with HR-positive EBC, TRA occurred in 62% with TCHP vs 35% for KP (OR=2.998; 95% CI 1.44-6.25). In those with HR-negative EBC, TRA was observed in 42% with TCHP vs. 21% with KP (OR=2.77; 95% CI 0.88-8.72). In the KP arm, TRA was observed in 38% (8/21) of pts. treated with standard adjuvant CT vs. 28% (20/71) of those that did not (OR 1.57; 95% CI 0.57-4.36). For women age ≤ 40, the rate of TRA was 38% with TCHP vs. 17% with KP (OR=3.00; 95% CI 1.05-8.60). For those &gt; 40 years, TRA was observed in 74% treated with TCHP vs. 39% of those with KP (OR=4.50; 95% CI 1.88-10.73). Conclusion: The rate of TRA with standard TCHP is nearly double that observed with KP, suggesting that targeted CT with an antibody-drug conjugate regimen is associated with less gonadal toxicity. Rates of TRA are higher in women over the age of 40 for each treatment arm however KP is associated with lower rate of TRA in each age group. Association of TRA with efficacy outcomes (pCR, iDFS) will be presented. Citation Format: Sara A Hurvitz, Rodrigo Fresco, Karen Afenjar, Daniil Stroyakovskiy, Chiun-Sheng Huang, Hans Wildiers, Kyung Hae Jung, Jean-François Boileau, Mario Campone, Miguel Martín, Vicente Valero, Joseph A. Sparano, W. Fraser Symmans, Peter A. Fasching, Alastair M. Thompson, Nadia Harbeck, Vanesa López-Valverde, Chunyan Song, Thomas Boulet, Eleonora Restuccia, Dennis J. Slamon. Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD12-06." @default.
• W3129853752 created "2021-03-01" @default.
• W3129853752 creator A5001315712 @default.
• W3129853752 creator A5011831123 @default.
• W3129853752 creator A5015491002 @default.
• W3129853752 creator A5017728105 @default.
• W3129853752 creator A5021239435 @default.
• W3129853752 creator A5021613406 @default.
• W3129853752 creator A5027231412 @default.
• W3129853752 creator A5027846283 @default.
• W3129853752 creator A5032340945 @default.
• W3129853752 creator A5037053656 @default.
• W3129853752 creator A5049348377 @default.
• W3129853752 creator A5052697647 @default.
• W3129853752 creator A5054850677 @default.
• W3129853752 creator A5068059897 @default.
• W3129853752 creator A5068222768 @default.
• W3129853752 creator A5071263994 @default.
• W3129853752 creator A5071553983 @default.
• W3129853752 creator A5080832682 @default.
• W3129853752 creator A5082890634 @default.
• W3129853752 creator A5085233304 @default.
• W3129853752 creator A5085875361 @default.
• W3129853752 date "2021-02-15" @default.
• W3129853752 modified "2023-10-02" @default.
• W3129853752 title "Abstract PD12-06: Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial" @default.
• W3129853752 doi "https://doi.org/10.1158/1538-7445.sabcs20-pd12-06" @default.
• W3129853752 hasPublicationYear "2021" @default.
• W3129853752 type Work @default.
• W3129853752 sameAs 3129853752 @default.
• W3129853752 citedByCount "0" @default.
• W3129853752 crossrefType "journal-article" @default.
• W3129853752 hasAuthorship W3129853752A5001315712 @default.
• W3129853752 hasAuthorship W3129853752A5011831123 @default.
• W3129853752 hasAuthorship W3129853752A5015491002 @default.
• W3129853752 hasAuthorship W3129853752A5017728105 @default.
• W3129853752 hasAuthorship W3129853752A5021239435 @default.
• W3129853752 hasAuthorship W3129853752A5021613406 @default.
• W3129853752 hasAuthorship W3129853752A5027231412 @default.
• W3129853752 hasAuthorship W3129853752A5027846283 @default.
• W3129853752 hasAuthorship W3129853752A5032340945 @default.
• W3129853752 hasAuthorship W3129853752A5037053656 @default.
• W3129853752 hasAuthorship W3129853752A5049348377 @default.
• W3129853752 hasAuthorship W3129853752A5052697647 @default.
• W3129853752 hasAuthorship W3129853752A5054850677 @default.
• W3129853752 hasAuthorship W3129853752A5068059897 @default.
• W3129853752 hasAuthorship W3129853752A5068222768 @default.
• W3129853752 hasAuthorship W3129853752A5071263994 @default.
• W3129853752 hasAuthorship W3129853752A5071553983 @default.
• W3129853752 hasAuthorship W3129853752A5080832682 @default.
• W3129853752 hasAuthorship W3129853752A5082890634 @default.
• W3129853752 hasAuthorship W3129853752A5085233304 @default.
• W3129853752 hasAuthorship W3129853752A5085875361 @default.
• W3129853752 hasConcept C121608353 @default.
• W3129853752 hasConcept C126322002 @default.
• W3129853752 hasConcept C143998085 @default.
• W3129853752 hasConcept C203092338 @default.
• W3129853752 hasConcept C2777863537 @default.
• W3129853752 hasConcept C2778292576 @default.
• W3129853752 hasConcept C2779786085 @default.
• W3129853752 hasConcept C2781164504 @default.
• W3129853752 hasConcept C2781190966 @default.
• W3129853752 hasConcept C29456083 @default.
• W3129853752 hasConcept C530470458 @default.
• W3129853752 hasConcept C535046627 @default.
• W3129853752 hasConcept C71924100 @default.
• W3129853752 hasConceptScore W3129853752C121608353 @default.
• W3129853752 hasConceptScore W3129853752C126322002 @default.
• W3129853752 hasConceptScore W3129853752C143998085 @default.
• W3129853752 hasConceptScore W3129853752C203092338 @default.
• W3129853752 hasConceptScore W3129853752C2777863537 @default.
• W3129853752 hasConceptScore W3129853752C2778292576 @default.
• W3129853752 hasConceptScore W3129853752C2779786085 @default.
• W3129853752 hasConceptScore W3129853752C2781164504 @default.
• W3129853752 hasConceptScore W3129853752C2781190966 @default.
• W3129853752 hasConceptScore W3129853752C29456083 @default.
• W3129853752 hasConceptScore W3129853752C530470458 @default.
• W3129853752 hasConceptScore W3129853752C535046627 @default.
• W3129853752 hasConceptScore W3129853752C71924100 @default.
• W3129853752 hasIssue "4_Supplement" @default.
• W3129853752 hasLocation W31298537521 @default.
• W3129853752 hasOpenAccess W3129853752 @default.
• W3129853752 hasPrimaryLocation W31298537521 @default.
• W3129853752 hasRelatedWork W2091007248 @default.
• W3129853752 hasRelatedWork W2137228442 @default.
• W3129853752 hasRelatedWork W2343994751 @default.
• W3129853752 hasRelatedWork W2540085961 @default.
• W3129853752 hasRelatedWork W2587365770 @default.
• W3129853752 hasRelatedWork W2900007630 @default.
• W3129853752 hasRelatedWork W2901487801 @default.
• W3129853752 hasRelatedWork W3031287216 @default.
• W3129853752 hasRelatedWork W3031648518 @default.
• W3129853752 hasRelatedWork W4322772378 @default.
• W3129853752 hasVolume "81" @default.
• W3129853752 isParatext "false" @default.
• W3129853752 isRetracted "false" @default.
• W3129853752 magId "3129853752" @default.
• W3129853752 workType "article" @default.